Therapeutic interventions for critically ill people with Covid-19

 
Loading

Therapeutic interventions for critically ill people with Covid-19

09 Nov 2021
AGM Theatre 4
Virus-independent immunopathology is now recognised as a pathophysiological feature of COVID-19. The GenOMICC, ISARIC4C and ICECAP studies have contributed to an understanding of the genetics of host susceptibility, systemic inflammatory profiles, and tissue pathology in COVID-19. Disease mechanisms identified by these studies include aberrant myeloid cell activation and recruitment, and defective interferon responses. Host-directed anti-inflammatory therapies and anti-viral monoclonal antibodies improve survival. The current and emerging therapeutic strategies for people with critical illness due to Covid-19 will be discussed in the context of immunopathologic mechanisms of disease.
Speakers
Clark Russell, Clinical Lecturer in Infectious Diseases - University of Edinburgh Centre for Inflammation Research

GOLD SPONSOR

  • A. Menarini Farmaceutica Internazionale Srl

 

GOLD SPONSOR

  • Alexion Pharma

 

GOLD SPONSOR

  • BMS-Pfizer

 

GOLD SPONSOR

  • FUJIFILM SONOSITE

 

GOLD SPONSOR

SD

GOLD SPONSOR

GOLD SPONSOR

  

SILVER SPONSOR

  • Boston Scientific

 

SILVER SPONSOR

  • Bial Pharma

 

SILVER SPONSOR

  • The MDU

 

SILVER SPONSOR

  • MDDUS

 

SILVER SPONSOR

GF

SILVER SPONSOR

JK

SILVER SPONSOR

SILVER SPONSOR

  

Don't miss your chance to get involved